Churro Recall Map as Warning Issued in 13 States
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Camerican International is recalling boxes of their Aldi Brand Casa Mamita Churro Bites in certain states due to fears of undeclared milk.
Newsweek reached out to the company via email Wednesday for comment.
Why It Matters
Numerous recalls have been initiated in 2025 due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens.
Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts.
The FDA warns that people with an allergy or sensitivity to milk run the risk of a potentially life-threatening reaction if they eat the recalled churro bites.
What To Know
In an FDA alert on Tuesday, the churro bites filled with chocolate hazelnut cream were sold at certain Aldi locations in Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina and Tennessee.
The recalled product was packaged in a 7.05-ounce box with a lot number of 01425 and a best by date of July 14, 2025. The FDA says that there have been no reported illnesses related to this recall.
Below is a map of the states impacted by the recall:
What People Are Saying
The FDA in the alert in part: "The recall was initiated after a consumer discovered that the milk-containing product was distributed in packaging that did not reveal the presence of milk. Subsequent investigation indicates the problem was caused by a temporary breakdown in the company's production and packaging processes that has subsequently been corrected."
In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service.
"The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued.
It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled."
Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts.
What Happens Next
Customers who have purchased the recalled product are urged to return it to the original place of purchase for a full refund, the FDA says.
People with any additional questions may call the company at 1-201-587-0101 on weekdays from 8:30 a.m. to 5 p.m. ET.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Buzz Feed
38 minutes ago
- Buzz Feed
Breaking My Silence: A 56-Year Secret That Saves Lives
'If your period is late, here's what you do: Boil up half a bottle of red wine and drink it while it's hot. Then stand on a chair and jump off several times. That should take care of it.' It was March 1957, and I'd just finished packing my trunk. I would be leaving the next day to sail from England to the United States, where I would marry Ezra, my soldier-fiancé. Those were my mother's final words of advice. Not 'never go to bed angry,' or 'pick your battles,' but how to abort a fetus. Her recommendation was unusual. Knitting needles were the instrument of choice for many British women trying to abort. Fewer Americans are knitters, so before Roe v. Wade made abortion legal in 1973, many women in the United States — or individuals from whom they sought assistance to end their pregnancies — used wire coat hangers. My mother believed her alternative method was a safe one. I smiled to myself, for I was pretty sure her instructions were useless. Only married women had access to contraception in the United Kingdom, so I planned to be fitted with a diaphragm as soon as I arrived in America. I was confident I would be able to avoid any unplanned pregnancies. The day after I landed, I looked up 'obstetricians and gynecologists' in the yellow pages and found a doctor nearby. I was disappointed when she refused to fit me, telling me I should come back after I was married. Just like in Britain, the United States only provided contraception to married women at that time. My wedding was two weeks away. What did this doctor think was going to happen on my honeymoon? Our first child, Ruth, was born after we'd been married for two years — just as Ezra and I planned. Dan was born 21 months later. Although I was often exhausted, I found taking care of two little children exhilarating. Watching their development was an unfolding miracle. Then, three and a half years later, when we were living in Palo Alto, California, I discovered I was pregnant again. While I was still in the throes of morning sickness, Ruth and Dan both came down with German measles, aka rubella. Everyone knew if you caught it when you were pregnant, especially in the first trimester, the baby was at high risk for serious birth defects like deafness, cataracts, heart malfunctions, developmental disabilities, and liver and spleen damage. The baby might also be stillborn. I asked my obstetrician what he would do if I contracted rubella. 'Nothing,' he replied with a shrug. A pregnant friend got rubella from one of her children and received the same answer from her doctor. She attempted suicide because of it and spent the rest of her life in a vegetative state. After our third child, Jonathan, was born, we moved to Berkeley, where I was fitted with an IUD. Ezra's architectural practice was thriving, and he was teaching at UC Berkeley. His work involved frequent travel to the East Coast, and he was away for weeks at a time. I was being pulled in many different directions by three children with very different needs. I began to feel inadequate as a parent — out of my comfort zone and overwhelmed. I struggled to hold things together for five years. When Jonathan entered kindergarten in 1969, I was thrilled to be able to return to my studies at the University of California. Kindergarten was half a day, and I was able to coordinate my classes with his. Life finally took on a comfortable rhythm. One morning in October that year, I woke up feeling the familiar signs of early pregnancy. At first, I denied the possibility. Abortion was illegal, so I continued to rely on my IUD, considered the safest form of birth control available at the time. I had been told they were 99% effective, which meant I was now part of the unlucky 1%. The thought of a baby growing together with the IUD was terrifying. What damage could that cause? But, more than that, I knew I couldn't handle taking care of another baby. Life was just beginning to feel normal. The prospect of dealing with a fourth child filled me with dread. I made an appointment with my obstetrician, who confirmed I was pregnant. 'I suppose I'll have to resign myself to having another baby,' I said, my eyes stinging with tears. 'We thought our family was complete. I don't know how I'm going to manage. I'm afraid it'll push me over the edge.' 'It sounds as if you might not want another baby,' my doctor said. 'No. I really don't. I'm stretched so thin already.' 'Go home and talk to your husband. If the two of you decide you definitely don't want to continue the pregnancy, here's what you'll do,' he told me. 'Call my office and tell them you are having a lot of bleeding. They will tell you to go to the emergency room, and I'll meet you there.' I had been looking down into my purse, groping for a tissue. I felt my jaw drop as I raised my eyes to meet his. He was smiling and nodding slowly as he spoke. In his subtle, gentle way, he was offering me a choice — one I'd never anticipated would be possible for me. A sense of relief washed over my entire body. I had thought I was trapped, and I had been offered a way out. When Ezra and I talked after dinner, there were no doubts — neither of us wanted more children. The next day was Saturday. I called my doctor's office and lied to the receptionist about bleeding heavily. Ezra drove me to the hospital, where we met the doctor. The two men shook hands, and the doctor told my husband, 'Not to worry — I'll take good care of her.' As I was wheeled into the operating room, the nurse walking beside the gurney squeezed my hand. 'You'll be fine,' she said. That's the last thing I remember about the procedure. When I awoke from the anesthesia, I got dressed and waited for Ezra and the children to pick me up in the hospital lobby. They arrived in the late afternoon. They'd gone to a football game, and the children were still excited about it. That evening, Ezra and I hugged and shared our thoughts about how relieved we were. He was particularly attentive and brought a stool so I could put my feet up. After he washed the dishes, he slipped out and came back with a tub of butter pecan ice cream — my favorite — our special way of marking important occasions. I didn't mention the experience to any of my friends. I had broken the law, and if word got out about my doctor's willingness to perform this procedure, his life could be ruined. The threat of legal action scared me into silence. I've maintained that silence until now. What would I have done if my doctor hadn't opened up this window of opportunity? Friends were going to Mexico for abortions, but the status of medical care in that country was a mystery to me. I could have ended up with a botched procedure, as often happened with the illegal abortions that were performed in so-called back alleys in the United States. Or what if I didn't have access to health care in the first place or the money to pay for the procedure, as many other women and families did — and do — not have. I also believed only a properly trained obstetrician could be trusted to remove the IUD nestling in my uterus beside my growing baby. Its removal was another opportunity for mistakes to be made. I am risk-averse and would have probably turned down these choices and carried the fetus to term. I would have been an angry, depleted mother to all my children. Today, at the age of 92, my reproductive years are far in the past, but old age doesn't temper the anger I feel towards the legislators who exercise their power to order a woman to carry her pregnancy to term whether she wants to or not. Women seeking abortions are often portrayed as foolish teenagers, but thousands of mature women with families are being put in this position just like I was. Our current legislators believe a few fertilized cells are more important than a woman's quality of life — a quality of life that ripples through her existing family. Right-to-lifers scream about 'partial birth abortions' while women who have suffered and wept through such rare procedures because of serious health issues are viewed as murderers. I'm telling my story now because maybe it will help wake us up to the nightmare we've created. Had I been forced to have a fourth child, the impact would have been devastating — not only for me, but for my family. We have failed the many women who find themselves in the same position I was. I was afraid to speak up back then. I am speaking up now. We are back in the days before Roe v. Wade, a time when women are being denied control of their own bodies. Doctors are understandably afraid to follow my obstetrician's example. Miscarriages are looked on with suspicion and without sympathy for a woman's grief when she experiences one. Women with dangerous pregnancy complications are told to wait for 'nature to take its course,' which puts their lives at risk. Many have died. Stories about women who spend their lives regretting their abortions and dreaming about the child-who-might-have-been spread throughout antiabortion communities. My post-abortion experience was the opposite. It enabled us to have the family we wanted. I've had no regrets. I will always be grateful to my obstetrician who was willing to risk imprisonment and the loss of his career to perform my illegal abortion. Now that we've gone back in time, women who don't want to bear a child will still find ways to abort a fetus just as they did before abortions became legal. They'll just be forced to do it in unsafe and potentially deadly ways. We are going back to the days of coat hangers and knitting needles. Cynthia Ehrenkrantz is a writer and storyteller. She was born in Britain and immigrated to the United States in 1957. Her memoir, 'Seeking Shelter: Memoir of a Jewish Girlhood in Wartime Britain,' is available wherever books are sold. She lives in Westchester County, New York.
Yahoo
an hour ago
- Yahoo
The 7 dietitian-backed foods to eat for a balanced breakfast
Your mornings are busy enough without having to spend the time to decide what to make – and then having to actually make – a healthy, well-balanced breakfast. That's further complicated by the fact "healthy" can mean different things to different people. Some may be trying to lose weight. Some may be trying to gain weight. Some may be trying to increase the amount of nutritious food they eat in a day. Some may just need to grab anything they can get their hands on to make sure there's something in their stomach before running out the door. Marisa Moore, MBA, RDN, LD, a registered dietitian nutritionist and author of "The Plant Love Kitchen," breaks down everything you need to know about best breakfast nutrition practices. Looking for a healthy breakfast? Here's what to eat in the morning for a nutritious meal. How many calories should I eat for breakfast? The amount of calories someone should eat in a given meal can depend on several factors, including age, sex, height, weight, physical activity, pregnancy or lactation status and individual goals. For example, the current Dietary Guidelines for Americans recommends that a moderately active (defined as the equivalent to walking between 1.5 and 3 miles per day at 3 to 4 miles per hour) 35-year-old man should be consuming about 2,600 calories a day, while a moderately active 35-year old woman needs about 2,000. Women generally need fewer calories than men, and older adults generally need fewer calories than younger ones. These recommendations can also vary depending on whether a person is trying to lose, maintain or gain weight, too. Rather than focusing on how many calories someone should be eating at breakfast, nutrition experts suggest paying more attention to the variety of macronutrients you're serving yourself. "Start the day with a protein- and carbohydrate-rich meal for sustained energy until lunch time," Moore suggests. Adding healthy fats, such as chia seeds, walnuts, olive oil, avocado or full-fat yogurt to the equation is helpful. What is meal sequencing? Health experts explain whether the rising diet trend works. What should I eat for breakfast? Your morning menu doesn't have to be boring. These balanced breakfast options will give you the energy you need to get through the day. Vegetable-packed omelet with a side of fruit (pick your favorites!) Protein-rich Greek yogurt with walnuts and berries (a quick, no-cook option that Moore says will keep you full "for hours"). Oatmeal with a creamy nut or seed butter with a handful of berries (this one's vegan, if that's something you're looking for in a recipe). Leftover beans and rice or roasted broccoli with scrambled eggs or tofu ("Remember that breakfast can be anything you want it to be," Moore says). The U.S. Department of Agriculture's MyPlate (which in 2011 replaced the food pyramid you might be more familiar with) also offers dozens of healthy breakfast recipes, including apple oatmeal muffins, black bean burritos and Spanish omelets. This article originally appeared on USA TODAY: What to eat for breakfast, according to a dietitian
Associated Press
2 hours ago
- Associated Press
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This marks the second registrational Phase III study of lisaftoclax to receive clearance from both the FDA and EMA. The GLORA-4 study is simultaneously enrolling patients at participating centers in multiple countries, to accelerate the drug's path to potential market authorization. To date, lisaftoclax is the only Bcl-2 inhibitor being advanced in a registrational Phase III trial in higher-risk MDS globally. This study, if positive, may potentially end the longstanding treatment gap in higher-risk MDS, marking yet another major milestone in the global clinical development of lisaftoclax. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Globally, we still lack targeted therapies for first-line treatment of patients with higher-risk MDS, which represents a huge unmet clinical need. Currently, hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain the primary treatment options for higher-risk MDS. In earlier studies, lisaftoclax has demonstrated promising clinical benefit and tolerability. The clearances of the GLORA-4 study by the U.S. FDA and EMA, coinciding with the approval by the China CDE, pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS and the first targeted therapy approved for this indication since the introduction of HMA, which fundamentally reshapes the treatment landscape.' The GLORA-4 trial is being conducted simultaneously in China, the U.S., and Europe. This will significantly accelerate the clinical development of lisaftoclax in MDS and accelerate the drug's path to potential market authorization. Moving forward, we will remain steadfastly committed to our mission of addressing unmet clinical needs in China and around the world, actively advancing our clinical programs for the benefit of more patients.' GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA compared to placebo plus AZA in newly diagnosed adult patients with higher-risk MDS. The study was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients already enrolled in China and Europe. Guillermo Garcia-Manero, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), and Prof. Xiaojun Huang, MD, an academician of the Chinese Academy of Engineering, director of the Institute of Hematology at Peking University, and director of the Department of Hematology at Peking University People's Hospital, are global co-leading principal investigators of the study. MDS is a myeloid clonal disease originating from hematopoietic stem cells with strongly age-correlated characteristics. Global epidemiological data of MDS show an exponential increase in incidence with age (22/100,000 in the population aged over 65 years), with a median age of diagnosis of 70 years1. More than 75% of patients with MDS present a complex disease profile that includes at least two comorbidities2. The primary risk of MDS is clonal evolution leading to progression to acute myeloid leukemia (AML), with 40-60% of higher-risk patients (high/very high risk, as classified by IPSS-R) progressing to AML within five years3. These patients have a dismal prognosis and a median survival of less than six months4. As the standard first-line therapy for higher-risk MDS, HMAs offer inadequate responses to treatment, with an overall response rate (ORR) of just 30-40%5, a complete response (CR) rate of 10-17%, and a median duration of response of 9-12 months6, 8. While allo-HSCT can offer a potential cure, it is limited by the median age of patients, complex disease profiles, common depletion of the hematopoietic stem cell reserve, and a transplantation-related mortality (TRM) rate of 25-35%. As a result, only 5-10% of eligible patients can receive transplantation7. The five-year survival rate of patients who are classified by the IPSS-R as high-risk remains at 16-24%8, highlighting an urgent unmet medical need for innovative therapies that can change the treatment paradigm. Lisaftoclax is a proprietary, novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is already approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. Previously, the Company released the clinical data of lisaftoclax in combination with AZA in treatment-naïve (TN) MDS during the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showed an ORR of 75%, much higher than HMAs alone, which demonstrated the clinical benefit of the combination regimen. The combination also showed a favorable safety profile, with a low incidence of severe hematologic toxicities and neutropenia-related infections. In addition, the proportion of patients requiring dose adjustments was low and there were no treatment-related mortalities within 60 days9, 10. Professor Huang commented, 'Despite the significant advancement in the treatment of hematologic malignancies, higher-risk MDS remains a major clinical challenge because of a range of factors. First, the current standard of care treatment with HMAs only offers limited efficacy, with just about one-third of patients achieving a response to treatment. Second, no breakthrough therapies have emerged globally in the two decades since the introduction of HMAs. As a result, there is an unmet clinical need for targeted therapies for higher-risk MDS. The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging. We hope this global Phase III study has the potential to provide new insights that could benefit how we treat and manage higher-risk MDS.' Dr. Garcia-Manero commented, 'Higher-risk MDS is more prevalent in older populations and thus presents unique clinical challenges. These patients often have multiple comorbidities and depleted hematopoietic reserves, making them less tolerant of treatment with particularly high requirement for safety. Preliminary clinical data of lisaftoclax demonstrated notable clinical benefit, with low rates of treatment-related dose adjustments and mortalities while maintaining significant response rates. We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients.' References: About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST. The second lead asset, lisaftoclax, is the first China-approved third-generation Bcl-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL who were previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher-risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma [email protected] +86 512 85557777 Stephanie Carrington ICR Healthcare [email protected] +1 (646) 277-1282 Media Relations: Jon Yu ICR Healthcare [email protected] +1 (646) 677-1855
